Linvoseltamab
Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) [1][2][3].
Product Specifications
CAS Number
2408319-25-3
Product Name Alternative
REGN5458
UNSPSC
12352203
Target
CD3; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/linvoseltamab.html
Purity
99.71
Solubility
10 mM in DMSO|H2O
Smiles
[Linvoseltamab]
Molecular Weight
(145.51 kDa)
References & Citations
[1]Lee H C, et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma[J]. 2023.|[2]Linvoseltamab. IMGT/mAb-DB.|[3]DiLillo DJ, et al., A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5 (5) :1291-1304.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC882354-500 1x 500 µL
FOLH1 / PSMA (Prostate Epithelial Marker) (FOLH1/2354), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 